TrimRX
US$ 26.61
gen tirz tirzepatide | GLP-1R and GIPR ligand | Sterile Personalized Compounded Tirzepatide Treatment
Description
Start your online visit.
The new rule would expand access to drugs such as Wegovy and Zepbound for an additional 3.4 million Americans who use Medicare and another 4 million people enrolled in Medicaid.
Disclosure: I hold a bullish position in Altimmune (ALT) through call options expiring January 2027 a leveraged, directional position that profits if the stock rises
User Feedback & Real-World Insights
A budget-busting 3.6 million Medicare recipients could now be eligible for coverage of the weight-loss drug Wegovy, a new KFF analysis says.
